Skip to main content
Device Profile

Abbott Lingo: What the Research Says About Glucose Monitoring

Abbott's over-the-counter glucose sensor, built on the same platform as its prescription FreeStyle Libre line. Here's what's actually verified about it.

Lingo is Abbott's consumer glucose-monitoring product, cleared for sale without a prescription and aimed at people who want to see their own glucose patterns rather than manage a diagnosed condition. It runs on sensor technology derived from Abbott's FreeStyle Libre 3 platform, the same underlying hardware used in its prescription CGMs, wrapped in a consumer-facing app. Below is what's actually verified about it, separate from marketing claims made by comparison sites that don't cite a primary source.

What Does Lingo Actually Measure?

Lingo measures interstitial glucose continuously and reports it through two proprietary metrics: a "Lingo Score" and "Lingo Counts," rather than the clinical-standard Time in Range figure directly. That's a meaningfully different design choice from Dexcom's Stelo, which shows Time in Range unmodified.

Reading frequencyMinute-by-minute glucose readings
Intended population18 years and older, not on insulin
Prescription requiredNo (over-the-counter)
Price$54 for an initial 2-week plan, 30-day money-back guarantee for first-time purchasers
App compatibilityiOS and Android, integrates with Apple Health and Health Connect

Abbott's own materials describe a "typical" healthy-range glucose band of 70-140 mg/dL and state plainly that Lingo is "not intended for diagnosis of diseases, including diabetes." Abbott's own guidance recommends consulting a healthcare professional before making dietary or exercise changes based on the data.

Sources: Abbott's own product documentation (hellolingo.com), accessed for this page
Full CGM metric identity →

Is Lingo FDA Cleared?

Yes. The FDA cleared the "Lingo Glucose System" (applicant: Abbott) on May 29, 2024, as a traditional 510(k) clearance, alongside a related over-the-counter CGM, Libre Rio, in the same clearance window.

As with Stelo, FDA clearance establishes the device met the agency's safety and performance requirements for its stated intended use. It doesn't independently validate the newer, separate question of what glucose patterns mean for a healthy person wearing it out of curiosity rather than managing a diagnosis, covered below.

Sources: FDA 510(k) database, K233655, decision date 2024-05-29 (openFDA)
Full CGM metric identity →

How Accurate Is Lingo?

Multiple third-party CGM-comparison sites report a MARD figure for Lingo in the high single digits to roughly 10 percent, generally placed in a similar general range to other current-generation OTC sensors. None of the specific percentages in wide circulation were traceable to Abbott's own primary published accuracy statement during research for this page.

Worth knowing

This is the same caution this site's CGM metric page already flags for both OTC sensors: treat any specific MARD percentage for Lingo as approximate until confirmed against Abbott's own primary accuracy statement, not a comparison site's paraphrase of it.

Sources: Attempted retrieval of FDA 510(k) K233655 summary and Abbott primary documentation; unresolved as of this page's last update
Full CGM metric identity →

What Does the Research Actually Say About Non-Diabetic CGM Use?

Separately from Lingo as a specific product, a growing body of research looks at what continuous glucose data means for people without diabetes: whether glucose spikes shown to a healthy person carry the same significance they would in someone with impaired glucose control, and whether wearing a CGM changes eating or exercise behavior just by being worn.

That evidence base is real but still developing, newer and thinner than the decades of diabetes-management CGM research it's often compared against.

Sources: Continuous Glucose Measurements for Diet Monitoring in Healthy Adults, Journal of Diabetes Science and Technology, 2026, doi:10.1177/19322968251361555; A Scoping Review of Glucose Spikes in People Without Diabetes, Clinical Medicine Insights: Endocrinology and Diabetes, 2025, doi:10.1177/11795514251381409
Full article: what a CGM shows without diabetes →

What Lingo Doesn't Do

Real, structural limitations tied to what a single-purpose glucose sensor is built for.

×

No other wearable metrics

Lingo is a glucose sensor only. It doesn't track HRV, sleep, steps, or heart rate the way a watch or ring does, and doesn't currently have a live integration with any wearable brand this site profiles, unlike Stelo's Oura integration.

×

Not for insulin users or diagnosed diabetics

Abbott is explicit that Lingo is not intended to diagnose diabetes or any other disease, and its clearance is specific to people 18 and up who are not on insulin.

Research Desk · live file
See the full CGM evidence file
Every claim rated Established, Emerging, Uncertain, Insufficient, or Unsupported, and reviewed on a rolling basis against new studies.
Open the Research Desk

Lingo's real differentiator is a simplified, gamified consumer framing, a Score and a Counts figure, over the clinical Time in Range language Stelo shows directly. That's a genuine design-philosophy difference, not a marketing footnote. What it can't offer yet, same as Stelo, is a confirmed primary-source accuracy figure or a wearable-brand integration on this site.

CGM comparison
Other devices